Haleon (LON:HLN) Sets New 52-Week High – Time to Buy?

Haleon plc (LON:HLN)’s stock price hit a new 52-week high on Thursday . The company traded as high as GBX 715.10 ($8.93) and last traded at GBX 370.80 ($4.63), with a volume of 56901801 shares. The stock had previously closed at GBX 371.40 ($4.64).

Haleon Stock Performance

The company’s 50-day moving average is GBX 375.68 and its two-hundred day moving average is GBX 372.52. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 54.18. The company has a market cap of £33.59 billion, a P/E ratio of 3,096.67, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19.

Insider Activity

In other Haleon news, insider Alan Stewart bought 33,923 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was purchased at an average price of GBX 368 ($4.59) per share, for a total transaction of £124,836.64 ($155,870.45). Also, insider Dawn Allen sold 74,679 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of GBX 372 ($4.64), for a total transaction of £277,805.88 ($346,867.12). Insiders own 10.74% of the company’s stock.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.